From the September 2013 issue of HealthCare Business News magazine
By Gary Dillehay, Peter Herscovitch, and Satoshi Minoshima
In June, the Centers for Medicare & Medicaid Services (CMS)
issued a proposed rule regarding coverage for the use of beta-amyloid positron emission tomography (PET) imaging agents. CMS agreed to cover one PET scan to exclude Alzheimer’s disease under a coverage with evidence development (CED) program — which grants conditional reimbursement upon collection of specific data — but only for patients participating in specific clinical studies.
The specific clinical trials that fall under the CMS requirements are long-term studies designed to develop better treatments or prevention strategies for Alzheimer’s disease, to identify subpopulations at risk, or to resolve clinically difficult differential diagnoses. It is proposed that patients enrolled in these studies continue until death, at which time autopsy is possibly performed. Given the length of these clinical trials and a significant burden on participating patients, it will take many years for researchers to collect data on the effect of brain amyloid imaging on health outcomes. Should this proposed rule be finalized, it will be a substantial amount of time before CMS would likely provide coverage for brain amyloid imaging.
Numed, a well established company in business since 1975 provides a wide range of service options including time & material service, PM only contracts, full service contracts, labor only contracts & system relocation. Call 800 96 Numed for more info.
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) believes that sufficient benefits and evidence exist to support immediate coverage, which would change patient management, leading to better health outcomes for patients and assisting families making care decisions. The current standard of care for Alzheimer’s disease and related dementing disorders is not necessary to attempt fundamental treatments or prevention alone. It is a quality of care and care arrangement based on best diagnosis available to patients. SNMMI believes that the proposed CED is not appropriate for the test and patient population, which the U.S. Food and Drug Administration has already approved, noting its clinical utility.
Earlier this year the Alzheimer’s Association and SNMMI jointly developed appropriate use criteria (AUC) to demonstrate that adequate evidence exists for Medicare to cover brain amyloid imaging without additional onerous steps. The criteria stated that for amyloid imaging to be considered appropriate, individuals must exhibit several characteristics. These include: (1) a cognitive complaint with objectively confirmed impairment; (2) Alzheimer’s disease as a possible diagnosis, but when the diagnosis is uncertain after a comprehensive evaluation by a dementia expert; and (3) knowledge of the presence or absence of amyloid-beta pathology is expected to increase diagnostic certainty and alter management.